Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
A 58-year-old man suffered relapse of multiple myeloma complicated by large intra-abdominal extramedullary plasmacytomas and severe hepatic impairment secondary to biliary obstruction. Previous treatment had included two types of combination chemotherapy and high-dose therapy with autologous stem cell transplant. Combination therapy with bortezomib and dexamethasone resulted in partial response of the plasmacytomas and complete resolution of his hepatic impairment. Extramedullary plasmacytomas are rare. This report lends support to the efficacy of bortezomib in the treatment of plasmacytoma and describes the safe use of bortezomib despite hepatic upset.
Hughes
M
M
Department of Haematology, Crosshouse Hospital, Kilmarnock, NHS Ayrshire and Arran, UK. marie@hughes1.co.uk
Micallef-Eynaud
P
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D008107:Liver Diseases / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000150:complications; D011719:Pyrazines / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone